Back to Search
Start Over
Real-World Outcomes of Anti-VEGF Treatment for Retinal Vein Occlusion in Portugal.
- Source :
-
European journal of ophthalmology [Eur J Ophthalmol] 2017 Nov 08; Vol. 27 (6), pp. 756-761. - Publication Year :
- 2017
-
Abstract
- Purpose: Retinal vein occlusion (RVO) is an important cause of visual disability in the modern world. We aim to evaluate the real-world outcomes of patients with RVO treated with anti-vascular endothelial growth factor (VEGF) in Portugal.<br />Methods: We performed a retrospective, observational, multicenter study including 8 centers across Portugal and 200 patients treated with either ranibizumab or bevacizumab. Data were collected at 3 time points: time of diagnosis (0 time point) and 6 and 12 months after initiating treatment. Demographic and clinical data were collected.<br />Results: Median visual acuity (VA) and central macular thickness (CMT) improved in the branch RVO (BRVO), central RVO (CRVO), bevacizumab, and ranibizumab groups at 6 and 12 months compared to baseline, with CMT improving further only in the CRVO and ranibizumab groups between 6 and 12 months (p = 0.002 and p = 0.001, respectively). The CMT was lower in the ranibizumab group compared to the bevacizumab group both at 6 and 12 months (p<0.02). Median CMT improved in both the good and poor baseline VA groups at 6 and 12 months compared to baseline (p<0.001). Median VA only improved for the group with poor baseline VA at 6 and 12 months of follow-up (p<0.001). Regression analysis identified several baseline variables as predictors of visual outcomes at 6 and 12 months, with different results depending on the analyzed group.<br />Conclusions: Both treatments were effective, although less effective than results reported in clinical trials. The morphologic response was better with ranibizumab compared to bevacizumab, although functionally there were no differences.
- Subjects :
- Adult
Aged
Aged, 80 and over
Female
Humans
Intravitreal Injections
Macula Lutea pathology
Macular Edema drug therapy
Male
Middle Aged
Portugal
Retinal Vein Occlusion complications
Retinal Vein Occlusion physiopathology
Retrospective Studies
Vascular Endothelial Growth Factor A antagonists & inhibitors
Visual Acuity physiology
Angiogenesis Inhibitors therapeutic use
Bevacizumab therapeutic use
Ranibizumab therapeutic use
Retinal Vein Occlusion drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1724-6016
- Volume :
- 27
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- European journal of ophthalmology
- Publication Type :
- Academic Journal
- Accession number :
- 28315518
- Full Text :
- https://doi.org/10.5301/ejo.5000943